Daniel E. Hilleman

4.5k total citations
147 papers, 3.3k citations indexed

About

Daniel E. Hilleman is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Daniel E. Hilleman has authored 147 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Cardiology and Cardiovascular Medicine, 40 papers in Surgery and 20 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Daniel E. Hilleman's work include Lipoproteins and Cardiovascular Health (22 papers), Cardiac electrophysiology and arrhythmias (22 papers) and Atrial Fibrillation Management and Outcomes (16 papers). Daniel E. Hilleman is often cited by papers focused on Lipoproteins and Cardiovascular Health (22 papers), Cardiac electrophysiology and arrhythmias (22 papers) and Atrial Fibrillation Management and Outcomes (16 papers). Daniel E. Hilleman collaborates with scholars based in United States, Brazil and China. Daniel E. Hilleman's co-authors include Syed M. Mohiuddin, Mark A. Malesker, Mitchell Friedman, Aryan N. Mooss, Kathleen A. Packard, Naresh A. Dewan, Thomas L. Lenz, Michele A. Faulkner, Dennis J. Esterbrooks and James M. Backes and has published in prestigious journals such as Journal of the American College of Cardiology, CHEST Journal and The American Journal of Medicine.

In The Last Decade

Daniel E. Hilleman

140 papers receiving 3.1k citations

Peers

Countries citing papers authored by Daniel E. Hilleman

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Hilleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Hilleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Hilleman more than expected).

Fields of papers citing papers by Daniel E. Hilleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Hilleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Hilleman. The network helps show where Daniel E. Hilleman may publish in the future.

Co-authorship network of co-authors of Daniel E. Hilleman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Hilleman. A scholar is included among the top collaborators of Daniel E. Hilleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Hilleman. Daniel E. Hilleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents 2023 ·Clinical Therapeutics ·(unknown), (unknown), Daniel E. Hilleman, Cheryl Gibson, James M. Backes	3
2	Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review 2020 ·Advances in Therapy ·Daniel E. Hilleman, Barbara S. Wiggins, Michael B. Bottorff	30
3	IMPACT OF OBESITY ON LONG-TERM OUTCOMES IN PATIENTS WITH ACUTE STEMI TREATED WITH PCI 2013 ·Journal of the American College of Cardiology ·(unknown), (unknown), Daniel E. Hilleman, Michael White, (unknown), Michael DelCore, Claire Hunter, Aryan N. Mooss, Dennis J. Esterbrooks	1
4	Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid 2010 ·Expert Opinion on Pharmacotherapy ·(unknown), (unknown), Daniel E. Hilleman, Mark A. Williams, Syed M. Mohiuddin	16
5	NICARDIPINE IN THE MANAGEMENT OF HYPERTENSION IN CRITICALLY ILL PATIENTS 2009 ·CHEST Journal ·Mark A. Malesker, (unknown), Daniel E. Hilleman	2
6	<b>Prevalence, Treatment, and Control of Hypertension in Residents of Skilled Nursing Facilities</b> 2008 ·The Consultant Pharmacist ·(unknown), (unknown), Michele A. Faulkner, Daniel E. Hilleman	2
7	Intensive Smoking Cessation Intervention Reduces Mortality in High-Risk Smokers With Cardiovascular Disease 2007 ·CHEST Journal ·Syed M. Mohiuddin, Aryan N. Mooss, Claire Hunter, (unknown), David Cloutier, Daniel E. Hilleman	192
8	New Concepts to Improve Health Outcomes for Patients With Chronic Obstructive Pulmonary Disease 2005 ·Journal of Managed Care Pharmacy ·(unknown), Richard D. Leff, Daniel E. Hilleman	1
9	Esmolol versus diltiazem in atrial fibrillation following coronary artery bypass graft surgery 2003 ·Current Medical Research and Opinion ·Daniel E. Hilleman, (unknown), Aryan N. Mooss, Kathleen A. Packard	16
10	Diagnostic and Prognostic Value of Holter-Detected ST-Segment Deviation in Unselected Patients With Chest Pain Referred for Coronary Angiography 2001 ·CHEST Journal ·Chandra K. Nair, Ijaz A. Khan, Dennis J. Esterbrooks, Kay Ryschon, Daniel E. Hilleman	9
11	Cost Effectiveness of Combination Therapy 1999 ·The American Journal of Managed Care ·Daniel E. Hilleman	11
12	Pharmacoeconomic Evaluation of a Combination of Ipratropium Plus Albuterol Compared With Ipratropium Alone and Albuterol Alone in COPD 1999 ·CHEST Journal ·Mitchell Friedman, Charles W. Serby, Shailendra Menjoge, J. Douglas Wilson, Daniel E. Hilleman, Theodore J. Witek	126
13	Effect of Oral H₂‐Receptor Antagonists on Left Ventricular Systolic Function and Exercise Capacity in Patients with Chronic Stable Heart Failure 1998 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·B. Daniel Lucas, Mark A. Williams, Syed M. Mohiuddin, (unknown), (unknown), Daniel E. Hilleman	6
14	Restenosis, the Achilles' Heel of Coronary Angioplasty 1998 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Richard L. Wurdeman, Daniel E. Hilleman, Aryan N. Mooss	10
15	Double‐Blind, Randomized, Placebo‐Controlled Evaluation of Atropine to Prevent Vasovagal Reaction During Removal of Femoral Arterial Sheaths 1997 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Bhola Rama, Syed M. Mohiuddin, Aryan N. Mooss, (unknown), Kay Ryschon, B. Daniel Lucas, Daniel E. Hilleman	7
16	Pharmacoeconomic evaluation of COPD: Stratification of outcomes and costs according to initial drug therapy 1996 ·CHEST Journal ·Daniel E. Hilleman, (unknown), (unknown)	1
17	Safety of Different Dosages of Intravenous Adenosine Used in Conjunction With Diagnostic Myocardial Imaging Techniques 1993 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Syed M. Mohiuddin, Dennis J. Esterbrooks, Naresh C. Gupta, Daniel E. Hilleman	6
18	Comparison of adenosine and exercise thallium-201 single-photon emission computed tomography (SPECT) myocardial perfusion imaging 1992 ·Journal of the American College of Cardiology ·Naresh C. Gupta, Dennis J. Esterbrooks, Daniel E. Hilleman, Syed M. Mohiuddin	139
19	Influence of Mexiletine on the Pharmacokinetics of Theophylline in Healthy Volunteers 1991 ·The Journal of Clinical Pharmacology ·(unknown), Syed M. Mohiuddin, Christopher J. Destache, (unknown), Daniel E. Hilleman	12
20	Long‐Term Antiarrhythmic Therapy With Cibenzoline 1987 ·The Journal of Clinical Pharmacology ·Syed M. Mohiuddin, Daniel E. Hilleman, Dennis J. Esterbrooks, Aryan N. Mooss, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact